Background A definitive diagnosis of immune‐mediated hemolytic anemia (IMHA) can be
difficult to make. However, it is critical to differentiate IMHA from other causes of anemia due …

Mycophenolic acid (MPA), a noncompetitive, selective and reversible inhibitor of inosine 5′‐
monophosphate dehydrogenase (IMPDH), is an immunosuppressive agent that has a long …

Background Breed predispositions, survival, and prognostic factors have not been evaluated
in dogs with nonregenerative immune‐mediated anemia (nrIMA). Hypothesis/Objectives To …

Background Immune-mediated haemolytic anaemia (IMHA) has a high mortality rate within
the first weeks to months of diagnosis. Identifying dogs at increased risk of death may help …

Materials and Methods: The study was conducted using 12 adults, apparently healthy
mongrel dogs. Immunosuppression was induced in six dogs by oral administration of …

There are limited data on glucocorticoid treatment in dogs. The purpose of this study was to
investigate whether dogs of higher body weight experienced more adverse events when …

Background Benefit of adding a second‐line immunosuppressive drug to glucocorticoids for
the treatment of non‐associative immune‐mediated hemolytic anemia (naIMHA) in dogs has …

Pulmonary thromboembolism (PTE) secondary to immune-mediated hemolytic anemia
(IMHA) is rarely diagnosed in cats. In this report, a 3-year-old cat was referred to our private …

Simple Summary Immune-mediated hemolytic anemia (IMHA) in dogs is a common
autoimmune disease which is accompanied with a high death rate and therapeutic …

OBJECTIVE To determine if oxidative stress induces phosphatidylserine (PS) externalization
in canine erythrocytes and if exposure to antioxidants prevents such changes. METHODS …